Hepatitis B Virus

Achillion inks agreement to evaluate next-generation antihepatitis and HIV agents

Published in AIDS Weekly, March 11th, 2002

ViroLogic, Inc., (VLGC) has inked an agreement with Achillion Pharmaceuticals, a privately held pharmaceutical company, to use ViroLogic's drug-resistance assays to evaluate Achillion's lead product candidate, ACH-126,443 (Beta-L-Fd4C), an L-nucleoside in clinical development for the treatment of HBV and HIV.

Under the terms of the agreement, Achillion can utilize ViroLogic's assays to evaluate its pipeline of investigational antiviral agents.

Achillion is currently evaluating Beta-L-Fd4C in chronically nfected HBV patients in a phase Ib/II clinical trial. Additional phase II studies are planned for 2002 to evaluate the drug in both chronic HBV and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-03-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry